Characterization and targeting of the function of the HNRNPC RNA binding protein in T-cell leukemia

Deregulated mRNA transcription and protein translation in the transformation of normal T-cells to malignant cells.

Characterize the role of kinases in controlling transcript homeostasis in acute leukemia

Characterizing and targeting aberrant splicing activity in acute leukemia

Characterizing and targeting the mechanisms of T-cell acute lymphoblastic leukemia blast metastasis in the central nervous system

Doctoral project Chaimae El Hadri

Drug response profiling of T-cell acute lymphoblastic leukemia to optimize salvage therapeutic strategies for refractory/relapsed patients

PROTACs to degrade oncogenic transcription factors in acute leukemia

BOF-ZAP professorship in cancer epigenetics

Characterize mechanisms of RNA and metabolic dysregulation in agressive leukemia

Characterizing and targeting aberrant splicing activity in acute leukemia

Characterizing and targeting the post-transcriptional and metabolic axis driving central nervous system involvement in T-cell acute lymphoblastic leukaemia.

Cofunding core facility - Flow cytometry

Cofunding Core Facility - Patient-derived xenograft models

Oncogenese en resistentie tegen therapie bij bloedkankers begrijpen en gerichten

On the road to excellence in unravelling the (epi)genetic landscape of hematologic neoplasms

The role of aberrant splicing in apoptosis and therapy resistance in T-cell leukemia

A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapies

Democratizing High-Throughput Next Generation Sequencing across different Life Science Fields: the AVITI Next Generation Sequencer.

ThirdGenT: linking third-generation sequencing of (epi)genomes, (epi)transcriptomes and translatomes to life sciences revolutionizes oncology, rare diseases, microbiology, cell and gene technology, developmental and computational biology

BOF-ZAP professorship in cancer epigenetics

Drug response profiling of T-cell acute lymphoblastic leukemia to optimize salvage therapeutic strategies for refractory/relapsed patients